See more : Fortistar Sustainable Solutions Corp. (FSSI) Income Statement Analysis – Financial Results
Complete financial analysis of Ionis Pharmaceuticals, Inc. (IONS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ionis Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- FedEx Corporation (FDX.SW) Income Statement Analysis – Financial Results
- JCDecaux SE (DEC.PA) Income Statement Analysis – Financial Results
- Zhejiang Yingfeng Technology Co., Ltd. (605055.SS) Income Statement Analysis – Financial Results
- Landmark Infrastructure Partners LP (LMRKN) Income Statement Analysis – Financial Results
- Greatwalle Inc. (8315.HK) Income Statement Analysis – Financial Results
Ionis Pharmaceuticals, Inc. (IONS)
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 787.65M | 587.00M | 810.00M | 729.00M | 1.12B | 599.67M | 507.67M | 346.62M | 283.70M | 214.16M | 147.29M | 102.05M | 99.09M | 108.47M | 121.60M | 107.19M | 69.62M | 24.53M | 40.13M | 42.62M | 49.99M | 80.18M | 53.27M | 37.26M | 33.90M | 39.20M | 32.50M | 22.60M | 13.00M | 10.10M | 12.10M | 8.70M | 6.30M | 2.00M |
| Cost of Revenue | 9.13M | 14.00M | 11.00M | 12.00M | 4.00M | 1.82M | 374.64M | 344.32M | 322.29M | 241.75M | 184.03M | 158.46M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -5.54M | -5.20M | -4.30M | -3.20M | -2.60M | -2.80M | -3.80M | 22.40M | -2.00M | 11.50M | 4.40M |
| Gross Profit | 778.51M | 573.00M | 799.00M | 717.00M | 1.12B | 597.85M | 133.02M | 2.30M | -38.59M | -27.59M | -36.75M | -56.41M | 99.09M | 108.47M | 121.60M | 107.19M | 69.62M | 24.53M | 40.13M | 42.62M | 49.99M | 80.18M | 53.27M | 42.79M | 39.10M | 43.50M | 35.70M | 25.20M | 15.80M | 13.90M | -10.30M | 10.70M | -5.20M | -2.40M |
| Gross Profit Ratio | 98.84% | 97.61% | 98.64% | 98.35% | 99.64% | 99.70% | 26.20% | 0.66% | -13.60% | -12.88% | -24.95% | -55.28% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 114.86% | 115.34% | 110.97% | 109.85% | 111.50% | 121.54% | 137.62% | -85.12% | 122.99% | -82.54% | -120.00% |
| Research & Development | 899.63M | 833.00M | 643.00M | 535.00M | 466.00M | 414.60M | 374.64M | 344.32M | 322.29M | 241.75M | 184.03M | 158.46M | 157.40M | 145.16M | 134.62M | 106.44M | 92.64M | 80.57M | 82.47M | 118.47M | 116.96M | 124.07M | 83.74M | 57.01M | 66.40M | 62.20M | 55.90M | 45.70M | 33.20M | 26.50M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 232.60M | 150.30M | 170.90M | 354.00M | 287.00M | 244.62M | 108.49M | 48.62M | 37.17M | 20.14M | 14.92M | 12.52M | 12.79M | 11.67M | 14.52M | 13.81M | 0.00 | 0.00 | 8.43M | 9.58M | 9.29M | 8.55M | 11.06M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 700.00K | 15.10M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -544.00K | -6.00K | 913.00K | -3.00M | 4.57M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 232.60M | 151.00M | 186.00M | 354.00M | 287.00M | 244.62M | 108.49M | 48.62M | 37.17M | 20.14M | 14.92M | 12.52M | 12.79M | 11.67M | 14.52M | 13.81M | 15.93M | 12.62M | 7.89M | 9.58M | 10.20M | 5.55M | 15.63M | 9.23M | 10.60M | 9.50M | 8.10M | 6.20M | 5.40M | 6.00M | 4.80M | 30.30M | 4.40M | 1.70M |
| Other Expenses | 0.00 | 3.00M | 9.00M | 2.00M | -686.00K | -182.00K | -3.55M | 18.42M | 40.93M | 39.24M | 39.84M | 59.36M | 61.21M | 42.24M | 26.49M | 7.59M | 59.05M | 64.94M | 60.27M | 118.28M | 70.21M | 54.63M | 47.92M | 5.54M | 5.20M | 4.30M | 3.20M | 2.60M | 2.80M | 3.90M | 3.20M | 2.00M | 900.00K | 400.00K |
| Operating Expenses | 1.13B | 984.00M | 829.00M | 889.00M | 753.00M | 659.23M | 483.13M | 392.94M | 359.47M | 261.89M | 198.95M | 170.97M | 170.19M | 156.83M | 149.14M | 120.25M | 108.57M | 93.19M | 90.36M | 128.05M | 127.17M | 129.62M | 99.38M | 71.78M | 82.20M | 76.00M | 67.20M | 54.50M | 41.40M | 36.40M | 8.00M | 32.30M | 5.30M | 2.10M |
| Cost & Expenses | 1.14B | 998.00M | 840.00M | 901.00M | 757.00M | 661.05M | 483.13M | 392.94M | 359.47M | 261.89M | 198.95M | 170.97M | 170.19M | 156.83M | 149.14M | 120.25M | 108.57M | 93.19M | 90.36M | 128.05M | 127.17M | 129.62M | 99.38M | 66.25M | 77.00M | 71.70M | 64.00M | 51.90M | 38.60M | 32.60M | 30.40M | 30.30M | 16.80M | 6.50M |
| Interest Income | 0.00 | 25.33M | 10.04M | 30.56M | 52.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.41M | 3.37M | 6.36M | 11.32M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 8.12M | 4.30M | 44.99M | 49.00M | 44.79M | 44.75M | 38.80M | 36.73M | 22.21M | 19.36M | 21.15M | 16.73M | 13.23M | 12.67M | 11.81M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 22.50M | 22.11M | 19.56M | 17.16M | 15.99M | 12.53M | 8.35M | 9.03M | 10.24M | 9.40M | 9.78M | 10.76M | 11.78M | 9.18M | 11.33M | 6.82M | 6.77M | 7.22M | 9.69M | 12.17M | 12.25M | 10.30M | 6.97M | 5.54M | 5.20M | 4.30M | 3.20M | 2.60M | 2.80M | 3.90M | 3.20M | 2.00M | 900.00K | 400.00K |
| EBITDA | -230.01M | -227.76M | -239.00K | -107.88M | 411.53M | -18.84M | 39.80M | -8.83M | -40.94M | -22.78M | -37.42M | -42.68M | -56.27M | -38.75M | -9.79M | 4.11M | -26.15M | -64.24M | -42.40M | -73.26M | -64.92M | -40.02M | -39.14M | -23.46M | -37.90M | -28.20M | -28.10M | -26.50M | -22.80M | -18.60M | -15.10M | -19.60M | -9.60M | -4.10M |
| EBITDA Ratio | -29.20% | -95.57% | -2.59% | -23.59% | 32.59% | -10.26% | 4.13% | -13.36% | -19.58% | -12.99% | -35.08% | -50.93% | -61.01% | -35.07% | -22.65% | -4.92% | -46.65% | -261.85% | -83.66% | -90.96% | -131.59% | -61.00% | -85.40% | -15.02% | -90.56% | -69.39% | -99.69% | -135.84% | -198.46% | -238.61% | -124.79% | -249.43% | -180.95% | -205.00% |
| Operating Income | -353.73M | -411.00M | -30.00M | -172.00M | 366.00M | -61.37M | 24.53M | -46.32M | -75.76M | -47.73M | -51.67M | -68.92M | -71.10M | -48.36M | -27.54M | -13.06M | -38.95M | -68.12M | -57.18M | -117.85M | -78.98M | -50.81M | -46.10M | -28.99M | -43.10M | -32.50M | -31.50M | -29.30M | -25.60M | -22.50M | -18.30M | -21.60M | -10.50M | -4.50M |
| Operating Income Ratio | -44.91% | -70.02% | -3.70% | -23.59% | 32.59% | -10.23% | 4.83% | -13.36% | -26.70% | -22.29% | -35.08% | -67.54% | -71.76% | -44.58% | -22.65% | -12.18% | -55.94% | -277.67% | -142.48% | -276.49% | -157.99% | -63.37% | -86.54% | -77.82% | -127.14% | -82.91% | -96.92% | -129.65% | -196.92% | -222.77% | -151.24% | -248.28% | -166.67% | -225.00% |
| Total Other Income/Expenses | 19.77M | 152.21M | 1.04M | 37.53M | -27.12M | -14.78M | -47.81M | -37.31M | -12.14M | -6.66M | -14.89M | -5.66M | -13.69M | -12.80M | -4.23M | -965.00K | 27.95M | -3.71M | -15.22M | -24.65M | -16.02M | -21.43M | -27.73M | -17.86M | -7.20M | -1.00M | 3.90M | 3.80M | 3.00M | 5.50M | 0.00 | 2.10M | 1.80M | 0.00 |
| Income Before Tax | -333.97M | -258.00M | -30.00M | -170.00M | 347.00M | -76.16M | -23.28M | -83.62M | -87.91M | -54.39M | -66.56M | -74.59M | -84.79M | -61.16M | -31.77M | -14.03M | -10.99M | -65.32M | -72.40M | -142.50M | -95.00M | -72.24M | -73.83M | -46.85M | -50.30M | -33.50M | -27.40M | -25.30M | -22.60M | -17.00M | 0.00 | -19.50M | -8.70M | 0.00 |
| Income Before Tax Ratio | -42.40% | -43.95% | -3.70% | -23.32% | 30.90% | -12.70% | -4.58% | -24.12% | -30.99% | -25.40% | -45.19% | -73.09% | -85.57% | -56.38% | -26.12% | -13.08% | -15.79% | -266.26% | -180.40% | -334.33% | -190.03% | -90.10% | -138.59% | -125.75% | -148.38% | -85.46% | -84.31% | -111.95% | -173.85% | -168.32% | 0.00% | -224.14% | -138.10% | 0.00% |
| Income Tax Expense | 32.32M | 12.00M | -1.00M | 317.00M | 44.00M | -291.14M | -5.98M | 2.93M | 372.00K | -15.41M | -5.91M | -9.11M | 11.00K | 92.00K | 3.19M | -1.10M | -27.95M | -22.75M | 22.18M | 57.08M | 17.82M | 6.79M | 8.89M | 24.50M | 16.10M | 10.50M | -400.00K | -2.80M | -1.90M | -4.30M | 800.00K | -2.10M | -1.80M | 0.00 |
| Net Income | -366.29M | -270.00M | -29.00M | -487.00M | 294.00M | 273.74M | -5.97M | -86.56M | -88.28M | -38.98M | -60.64M | -65.48M | -84.80M | -61.25M | 155.07M | -11.96M | -10.99M | -45.90M | -72.40M | -142.50M | -95.00M | -72.24M | -73.83M | -53.49M | -59.20M | -43.00M | -31.10M | -26.50M | -23.70M | -18.20M | -19.10M | -19.50M | -8.70M | -4.50M |
| Net Income Ratio | -46.50% | -46.00% | -3.58% | -66.80% | 26.18% | 45.65% | -1.18% | -24.97% | -31.12% | -18.20% | -41.17% | -64.16% | -85.58% | -56.47% | 127.52% | -11.16% | -15.79% | -187.11% | -180.40% | -334.33% | -190.03% | -90.10% | -138.59% | -143.56% | -174.63% | -109.69% | -95.69% | -117.26% | -182.31% | -180.20% | -157.85% | -224.14% | -138.10% | -225.00% |
| EPS | -2.56 | -1.90 | -0.21 | -3.49 | 2.10 | 2.07 | -0.05 | -0.72 | -0.74 | -0.33 | -0.55 | -0.65 | -0.85 | -0.62 | 1.58 | -0.13 | -0.13 | -0.62 | -1.15 | -2.52 | -1.71 | -1.33 | -1.67 | -1.44 | -2.06 | -1.60 | -1.17 | -1.04 | -1.10 | -0.93 | -1.22 | -1.51 | -0.84 | -0.70 |
| EPS Diluted | -2.56 | -1.90 | -0.21 | -3.49 | 2.06 | 2.04 | -0.05 | -0.72 | -0.74 | -0.33 | -0.55 | -0.65 | -0.85 | -0.62 | 1.58 | -0.13 | -0.13 | -0.62 | -1.15 | -2.52 | -1.71 | -1.33 | -1.67 | -1.44 | -2.06 | -1.60 | -1.17 | -1.04 | -1.10 | -0.93 | -1.22 | -1.51 | -0.84 | -0.70 |
| Weighted Avg Shares Out | 143.19M | 141.85M | 141.02M | 139.61M | 140.00M | 132.32M | 124.02M | 120.80M | 119.29M | 117.69M | 110.50M | 100.58M | 99.66M | 99.14M | 98.11M | 94.57M | 83.74M | 74.31M | 62.88M | 56.64M | 55.46M | 54.48M | 44.11M | 37.02M | 28.70M | 26.87M | 26.58M | 25.48M | 21.55M | 19.57M | 15.66M | 12.91M | 10.36M | 6.43M |
| Weighted Avg Shares Out (Dil) | 143.19M | 141.85M | 141.02M | 139.61M | 142.87M | 134.06M | 126.10M | 120.93M | 119.72M | 117.69M | 110.50M | 100.58M | 99.66M | 99.14M | 98.11M | 94.57M | 83.74M | 74.31M | 62.88M | 56.64M | 55.46M | 54.48M | 44.11M | 37.02M | 28.70M | 26.87M | 26.58M | 25.48M | 21.55M | 19.57M | 15.66M | 12.91M | 10.36M | 6.43M |
Ionis Pharmaceuticals (IONS) Upgraded to Buy: What Does It Mean for the Stock?
Ionis Pharmaceuticals (IONS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why Ionis Pharmaceuticals (IONS) is Poised for a Turnaround After Losing -13.46% in 4 Weeks
Ionis Pharmaceuticals (IONS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Ionis' Q3 Earnings and Revenues Beat Estimates, New Launches in Focus
IONS reports better-than-expected top and bottom-line numbers for the third quarter of 2024.
Ionis to present at upcoming investor conferences
CARLSBAD, Calif. , Nov. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Guggenheim's Inaugural Healthcare Conference on Wednesday, November 13, 2024 UBS Global Healthcare Conference...
Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q3 2024 Earnings Conference Call November 6, 2024 11:30 AM ET Company Participants Wade Walke – Senior Vice President of Investor Relations Brett Monia – Chief Executive Officer Eugene Schneider – Chief Clinical Development Officer...
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.03 per share a year ago.
Ionis Announces Pivotal Phase 3 Trial Design for ION582 in Angelman Syndrome
Positive End of Phase 2 discussion with FDA, including alignment on Phase 3 design Bayley-4 expressive communication selected as Phase 3 study primary endpoint Initiation of ION582 Phase 3 study planned for H1 2025 Ionis to share ION582 program update...
Ionis reports third quarter 2024 financial results
WAINUA TM U.S. launch progressing well; approved in UK; positive CHMP opinion Olezarsen FCS PDUFA December 19, 2024 Donidalorsen HAE PDUFA August 21, 2025; EU regulatory submission in process On track to achieve 2024 P&L financial guidance; increased 2024 cash...
Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for Ionis Pharmaceuticals (IONS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Source: https://incomestatements.info
Category: Stock Reports